Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Characterization of the Selectivity and Mechanism of Cytochrome P450 Inhibition by Dimethyl-4,4′-dimethoxy-5,6,5′,6′-
dimethylenedioxybiphenyl-2,2′-dicarboxylate

Ji-Yeon Kim, Minsun Baek, Sooyong Lee, Sung-Ok Kim, Mi-Sook Dong, Bok-Ryang Kim and Dong-Hyun Kim
Drug Metabolism and Disposition December 2001, 29 (12) 1555-1560;
Ji-Yeon Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minsun Baek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sooyong Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sung-Ok Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mi-Sook Dong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bok-Ryang Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dong-Hyun Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In vitro studies with human liver microsomes and cytochrome P450 (P450) prototype substrates were performed to characterize the selectivity and mechanism of inhibition of P450 by dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate (DDB). DDB was found to be a strong inhibitor of testosterone 6β-hydroxylation activity (CYP3A4) with aKi value of 0.27 ± 0.21 μM. At higher concentrations, DDB marginally inhibited caffeineN3-demethylation (CYP1A2), diclofenac 4′-hydroxylation (CYP2C9), and dextromethorphanO-demethylation (CYP2D6) activities, but this compound had no effect on CYP2A6-, CYP2C19-, and CYP2E1-mediated reactions. Spectral analysis indicated that the formation of metabolite-P450 complex having absorbance at 456 nm was concentration-dependent; 5 to 33% of the total P450 was complexed in rat and human liver microsomes after a 5-min incubation with DDB. In addition, microsomal incubations with DDB in the presence of NADPH resulted in a loss of spectral P450 content, which was restored after adding K3Fe(CN)6. This complex formation resulted in a time-dependent loss of CYP3A-catalyzed marker activity (testosterone 6β-hydroxylation) in human liver microsomes. The inhibition was only partially restored upon dialysis. These results collectively suggest that formation of a metabolite-CYP3A complex with DDB was responsible for the CYP3A-selective time-dependent loss of catalytic function of CYP3A.

Dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′- dicarboxylate (DDB1; Fig. 1) is an intermediate process of synthesizing Schizandrin C, a natural compound isolated from Fructus schizandrae chinensis. Clinical experience has shown that DDB is effective in lowering the serum glutamic pyruvic transaminase activity in patients with chronic viral hepatitis (Lee et al., 1991). DDB protects against carbon tetrachloride-, d-galactosamine-, and thioacetamide-induced hepatic injury (Liu and Lesca, 1982; Yu et al., 1987). Moreover, the enhanced effectiveness in combination with garlic oil (Kim et al., 1995) and the protective effect of DDB against ethanol-induced fatty liver (Kim et al., 1999) were reported. Currently, this drug is widely used in Asian countries.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Chemical structure of DDB.

Enzyme inactivation often causes an accumulation of drugs during chronic dosing and an increase of the apparent half-life with dose, and potential interactions with coadministered drugs can cause serious side effects in clinical aspects. One of the mechanisms of enzyme inactivation involves a quasi-irreversible coordination of a reactive intermediate(s) to the P450 (Murray and Reidy, 1990). Macrolide antibiotics, including oleandomycin, triacetyloleandomycin, erythromycin, roxithromycin, and clarithromycin, are major compounds to form metabolite-P450 complexes (Babany et al., 1988; Franklin, 1991;Bensoussan et al., 1995). In addition, methylenedioxyphenyl derivatives, such as 1,3-dioxazole and human immunodeficiency virus protease inhibitors, also undergo P450-catalyzed oxidation to form intermediates that coordinate tightly to the prosthetic heme iron (Philpot and Hodgson, 1972; Hodgson and Philpot, 1974; Chiba et al., 1998). DDB possesses the methylenedioxyphenyl moiety, and P450s were demonstrated to be the primary enzymes responsible for the metabolism of DDB in human liver microsomes (Baek et al., 2001).

The objectives of the present investigation were 1) to examine the potential for inhibition of human P450 by DDB, followed by the determination of the inhibition constants in human liver microsomes; and 2) to gain insight into the mechanism of inhibition for the P450 most potentially inhibited by DDB.

Materials and Methods

Chemicals.

DDB was supplied by Choongwae Pharma Corp. (Kyungki, Korea). Testosterone, glucose 6-phosphate, β-NADP+, β-NADPH, glucose-6-phosphate dehydrogenase, chlorzoxazone, caffeine, coumarin, diclofenac, and 7-hydroxycoumarin were purchased from Sigma Chemical Co. (St. Louis, MO). 6-Hydroxychlorzoxazone and ketoconazole were obtained from Sigma/RBI (Natick, MA). 6β-Hydroxytestosterone, 4-hydroxydiclofenac, dextromethorphan, dextrorphan, and 4-hydroxymephenytoin were purchased from Ultrafine (Manchester, UK). All other reagents used were highest grade commercially available.

Microsomal Preparation.

Rats were pretreated with a daily intraperitoneal injection of pregnenolone-16α-carbonitrile (PCN; 50 mg/kg in corn oil) for 3 consecutive days. Animals were killed 24 h after the last treatment. The livers were excised quickly and perfused with ice-cold 1.15% KCl solution. Human liver tissues were generously donated by Dr. Guengerich (Vanderbilt University, TN). Microsomal fraction was prepared according to the method described elsewhere (Guengerich et al., 1986), and the final pellets were resuspended in 10 mM Tris acetate buffer, pH 7.4, containing 1 mM EDTA and 20% (w/v) glycerol.

Microsomal Incubation.

For incubation studies designed to determine the effects of DDB on various P450 isozyme activities, the incubation mixture contained 0.5 mg/ml microsomal protein, NADPH-generating system (5 mM glucose 6-phosphate, 1 mM β-NADP+, and 1 U/ml glucose-6-phosphate dehydrogenase), DDB (0.25–50 μM), and various P450 isoform-specific substrates in 0.1 M phosphate buffer, pH 7.4. Substrate concentrations were used at approximately their respectiveKm values: 1 mM for caffeine, 5 μM for diclofenac, 20 μM for chlorzoxazone, 0.4 μM for coumarin, 40 μM for testosterone, 5 μM for dextromethorphan, and 80 μM for mephenytoin. DDB was dissolved in dimethyl sulfoxide, and other substrates were dissolved in methanol. The solvent was evaporated under a stream of nitrogen gas before adding the incubation mixture, and the final concentration of dimethyl sulfoxide did not exceed 0.5%. For the determination of the Ki value toward testosterone, testosterone concentrations of 10, 20, and 40 μM were used.

P450 Probe Substrate Assays.

Testosterone 6β-hydroxylation activity, an index of CYP3A activity, was done as described elsewhere with minor modification (Lee et al., 1994). The reaction was initiated, following a 3-min preincubation at 37°C, by addition of NADPH-generating system and allowed to proceed for 20 min. Reactions were terminated by addition of 2 volumes of methylene chloride, and corticosterone (10 μl of 200 μg/ml) was added as an internal standard. The organic layer was taken after vortexing for 2 min and evaporated to dryness under nitrogen stream. The residue was then dissolved in 100 μl of mobile phase. Sample aliquots (50 μl) were injected on a reverse phase C18 high-pressure liquid chromatography column (Ultrasphere ODS; 4.6 × 150 mm, 5 μm; Beckman Coulter, Inc., Fullerton, CA), using a Waters M600 liquid chromatography system (Waters, Milford, MA). The mobile phase consisted of 60% methanol in water, and the flow rate was 1.0 ml/min. The eluent was monitored at 254 nm, and the amount of 6β-hydroxytestosterone was determined by comparison to a standard curve.

Caffeine N3-demethylation for CYP1A2 (Lee et al., 1998), coumarin 7-hydroxylation for CYP2A6 (Yun et al., 1991), diclofenac 4′-hydroxylation for CYP2C9 (Leeman et al., 1993),S-mephenytoin 4′-hydroxylation for CYP2C19 (Relling et al., 1989), dextromethorphan O-demethylation for CYP2D6 (Dayer et al., 1989), and chlorzoxazone 6-hydroxylation for CYP2E1 (Peter et al., 1990) were determined in human liver microsomes according to methods described elsewhere. Each incubation was performed in duplicate.

Dialysis Experiments.

Pooled human liver microsomes were incubated with DDB in the presence or absence of NADPH for 20 min. Samples were immediately placed in 6000 to 8000 molecular weight cutoff dialysis tubing (Spectral Medical Industries, Los Angeles, CA) and dialyzed for 18 h at 4°C against 2000 ml of 0.1 M potassium phosphate buffer, pH 7.4, containing 5 mM EDTA. Protein content was subsequently measured, and testosterone 6β-hydroxylase activity was assayed after 20-min incubation.

Inactivation Studies.

To characterize the time-dependent inhibition of CYP3A4 activity by DDB, human liver microsomes (2 mg of protein/ml) were incubated with varying concentrations of DDB. The reaction mixture was preincubated at 37°C for 3 min before initiating the reaction by addition of NADPH (1 mM final concentration). At 0, 2, 5, 10, and 20 min after the incubation, a 25-μl aliquot of each incubation was taken from the primary reaction mixture and added to a secondary reaction mixture containing 200 μM testosterone and NADPH-generating system in 0.1 M potassium phosphate buffer, pH 7.4, in a final volume of 0.5 ml. The reaction was allowed to proceed for a further 20 min, and 6β-hydroxytestosterone formed in the reaction mixture was determined by high-pressure liquid chromatography analysis.

Spectral Analysis.

Metabolite-P450 complex formation was measured with liver microsomes obtained from humans and PCN-treated rats. The reaction mixture contained 50 mM Tris-HCl, pH 7.4, 150 mM KCl, 10 mM MgCl2, and 2 mg of microsomal protein in a final volume of 1 ml. DDB (dissolved in dimethyl sulfoxide) was added to the test cuvette, whereas the same volume of dimethyl sulfoxide (final concentration 0.5%) was added to the reference cuvette. After the baseline was corrected from 400 to 500 nm, the reactions were initiated by addition of NADPH (1 mM) to both cuvette at 37°C. The spectral changes between 400 and 500 nm due to metabolite-P450 complex formation were recorded using a JASCO V-550 UV/VIS spectrophotometer (JASCO, Tokyo, Japan).

For the measurement of P450 content, pooled human liver microsomes (1.0 mg/ml) were incubated in duplicate at 37°C in a shaking water bath. P450 content was determined in samples containing human liver microsomes only, human liver microsomes plus NADPH (1.0 mM) or DDB (25 μM), and human liver microsomes plus NADPH (1.0 mM) and DDB (25 μM). At 0, 1, 5, 10, and 20 min, each incubation mixture was transferred to ice-bath, and P450 content was analyzed within 30 min. The zero time point was the baseline condition before the addition of components to microsomes. For the determination of concentration-related changes of P450 content, rat, and human liver microsomes were incubated with DDB in the presence of NADPH for 20 min. P450 content was measured by established method (Omura and Sato, 1964), with an extinction coefficient of 91 mM cm−1using a JASCO V-550 UV/VIS spectrophotometer.

Data Analysis.

The IC50 values were obtained from a plot of percentage activity remaining (relative to solvent alone incubate) versus log10 of DDB concentration (0.05–10 μM). Inhibition data were graphically represented by Lineweaver-Burk (one per initial rate versus one per substrate concentration) and Dixon (one per initial rate versus inhibitor concentration) plots, and type of inhibition was determined using both plots. Estimates of inhibition constant (Ki) were determined using secondary plot of Lineweaver-Burk (slope versus inhibitor concentration) and mean value of three independent experiments was presented.

Results

Selectivity of DDB on the Inhibition of P450 Isoforms.

The inhibition of P450 isoforms by DDB was investigated by using various P450 isoform-specific probe substrates (Table1). DDB did not significantly inhibit the CYP2A6-, CYP2C9-, and CYP2C19-mediated reactions up to 50 μM DDB. Caffeine N3-demethylase (CYP1A2), dextromethorphan O-demethylation (CYP2D6), and chlorzoxazone 6β-hydroxylase (CYP2E1) were inhibited by DDB, but the extent of inhibition was less than 50% even at the highest concentration of DDB. Testosterone 6β-hydroxylation, a marker activity of CYP3A4, was markedly inhibited in the presence of DDB with the IC50 value of 0.38 μM. Figure2 shows a double reciprocal (Lineweaver-Burk) plot of substrate concentration versus testosterone 6β-hydroxylation and a Dixon plot of inhibitor concentration versus testosterone 6β-hydroxylation by HL114 microsomes. The Lineweaver-Burk plot tended to intersect on the y-axis, and Dixon plot intersected above the x-axis, indicating that DDB inhibited the reaction in a competitive mode over the substrate range of 10 to 40 μM testosterone. The apparentKi value, obtained by secondary plot of Lineweaver-Burk, was estimated to be 0.27 ± 0.21 μM in human liver microsomes (Table 2).

View this table:
  • View inline
  • View popup
Table 1

Effect of DDB on P450 isoform-specific marker activities in human liver microsomes

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Lineweaver-Burk (A) and Dixon (B) plot for DDB-induced inhibition of testosterone 6β-hydroxylation in human liver microsomes.

Human liver microsomes (0.5 mg/ml) from HL114 were incubated with various concentrations of testosterone in the presence of increasing amounts of DDB.

View this table:
  • View inline
  • View popup
Table 2

Inhibition constants characterizing the inhibition of human liver microsomal CYP3A4 in the presence of DDB

Time-Dependent Inhibition of Testosterone 6β-Hydroxylation.

As shown in Fig. 3, DDB caused a time- and concentration-dependent inactivation of CYP3A4 with a NADPH-dependent manner. Significant inhibition was observed in the zero-time samples, probably due to the residual DDB since the initial incubation was diluted only 20-fold to retain sufficient sensitivity for testosterone 6β-hydroxylation assay. Dialysis experiments were performed to evaluate whether CYP3A4 activity could be restored to that of control after a 20-min incubation with DDB and NADPH. After an 18-h dialysis, microsomes were incubated with testosterone for 20 min, and testosterone 6β-hydroxylase activity was measured (Table3). After dialysis of the samples incubated without NADPH, testosterone 6β-hydroxylation activity was restored near to control level. In the case of the samples incubated with NADPH, the activity was partially restored at all concentrations of DDB in comparison with undialyzed samples, suggesting that the inhibition of the activity is partly due to the inactivation of the enzyme by DDB.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Time- and concentration-dependent loss of testosterone 6β-hydroxylation activity in human liver microsomes with various concentrations of DDB.

The human liver microsomes were preincubated with 0.5 to 5 μM DDB, 1 mM NADPH, and 2 mg/ml microsomal protein. At the indicated time points, 25 μl of the incubation mixture was added to 475 μl of reaction mixture containing 200 μM testosterone and NADPH-generating system, and further incubated for 20 min. Each point is the average of three determinations.

View this table:
  • View inline
  • View popup
Table 3

Recovery of testosterone 6β-hydroxylase activity after an 18-h dialysis following a 20-min preincubation with DDB and NADPH in human liver microsomes

Metabolite-P450 Complex Formation.

NADPH-dependent metabolite-P450 complex formation by DDB was measured in rat and human liver microsomes. When DDB was added to liver microsomes in the presence of NADPH, a maximum of 456 nm in the absorbance spectrum developed, indicating the formation of metabolite-P450 complex. No such maximum was obtained in the absence of NADPH. Approximately 40% of the initial P450 gave the reduced CO-P450 spectrum in the presence of dithionate (Fig.4). The formation of metabolite-P450 complex increased dose dependently in PCN-treated rat microsomes, whereas the formation of metabolite-P450 complex was observed only at a high concentration of DDB in human liver microsomes (Table4).

Figure 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4

Metabolite-P450 complex spectrum in PCN-treated rat liver microsomes.

Spectrum a represents the baseline spectrum, and spectrum b was recorded after a 5-min incubation with 100 μM DDB and 1 mM NADPH in PCN-treated rat liver microsomes. Then, the reduced CO-difference P450 spectrum (c) was recorded. Spectrum d represents the reduced CO-difference P450 spectrum obtained before incubation with DDB. Abs, absorbance.

View this table:
  • View inline
  • View popup
Table 4

Metabolite-P450 complex formation by DDB in PCN-treated rat and human liver microsomes

Effect of DDB on P450 Content in Microsomes.

As an indirect evidence for P450 inactivation, P450 content changes were measured after incubation of DDB with human liver microsomes. DDB in the absence of NADPH did not result in a loss of P450 content in microsomes, whereas the addition of NADPH to reaction mixture resulted in a 45% loss of P450 content after 20 min (Fig.5). NADPH itself also decreased the P450 content by 20%, as previously observed (Chiba et al., 1995). The loss of P450 content was also observed in rat liver microsomes (Table5). When potassium ferricyanide was added to microsomes, the amount of P450 content was restored to the control level, resulting from the disruption of the metabolite-P450 complex (data not shown).

Figure 5
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5

Time-dependent loss of P450 content in human liver microsomes.

Human liver microsomes (1 mg of protein/ml) were incubated in duplicate at 37°C. At the designated time points, the P450 concentrations were measured by reduced CO-difference P450 spectra. ●, microsome control; ▿, 25 μM DDB; ○, 1 mM NADPH; ▾, 25 μM DDB + NADPH.

View this table:
  • View inline
  • View popup
Table 5

Changes in P450 content after incubation of DDB with PCN-treated rat and human liver microsomes in the presence of NADPH

Discussion

The human liver microsomal studies described in these experiments showed that only CYP3A4 was inhibited at clinically relevant concentrations of DDB with a Ki value of 0.27 μM. DDB had little or no effects on the activities of CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, and CYP2E1. All of the IC50 values toward these isoforms were above 50 μM, which is about 50-fold greater than the typicalCmax (∼1 μM). These findings suggest that DDB drug interactions involving the CYP3A family are possible, whereas clinical interactions of other isoforms are not expected.

Incubations of DDB with human liver microsomes demonstrated that time-dependent inhibition of CYP3A4 was not observed for DDB alone; however, the addition of NADPH to the preincubation mixture containing DDB and human liver microsomes resulted in a time-dependent loss of CYP3A4 activity. Furthermore, the inhibition was only partially restored after the dialysis of incubation mixture. The dialysis of samples incubated in the absence of NADPH restored the activity to near control level, suggesting that the inhibition of the activity of samples incubated in the presence of NADPH after the dialysis was not due to the residual DDB. These results can be attributed to the formation of a metabolite-P450 complex with DDB. Methylenedioxyphenyl compounds have long been recognized as effective in vitro inhibitors of microsomal oxidation, and the ability is widely attributed to their oxidative metabolism to a reactive metabolic intermediate, possibly a carbene, that forms a stable inhibitory complex with ferrocytochrome P450 (Marcus et al., 1985; Murray et al., 1985). DDB also has methylenedioxyphenyl moiety and is metabolized to catechol derivatives through the initial hydroxylation of methylene carbon (Baek et al., 2001). Consequently, DDB can generate a reactive metabolic intermediate that coordinates tightly to the heme of P450, like other methylenedioxyphenyl compounds. The peak at 456 nm due to the complex formation was detected in human liver microsomes when DDB was incubated in the presence of NADPH. The formation of metabolite-P450 complex was increased in a concentration-dependent manner, and the maximum complex formation was estimated to be about 33% at 100 μM. It is suggested that the extent of metabolite-P450 complex formation is dependent on the side chain substituent on the methylenedioxy moiety. Complex formation is increased when the substituent is an electron-donating or a long-alkyl group, which stabilizes the carbene-iron bridges (Mansuy et al., 1979; Chiba et al., 1998). The relatively high extent of metabolite-P450 complex may be due to the presence of the methoxy group on the phenyl ring of methylenedioxyphenyl moiety.

The inhibition of CYP3A4 activity via the formation of a metabolite-P450 complex was further supported by the diminished P450 content. Since P450 that has the heme occupied by a ligand cannot bind carbon monoxide, the amount of metabolite-P450 complex formed can be determined by the loss of carbon monoxide binding. P450 content decreased when DDB was incubated with human liver microsomes or reconstituted CYP3A4 enzyme in the presence of NADPH. The loss of P450 was restored when the incubation mixture was treated with potassium ferricyanide, suggesting that the enzyme-DDB related complex is considered tight and noncovalent in nature. Considering that the activity was only partially regained after dialysis at 4°C, the metabolite-P450 complex was tight enough not to be easily dissociated.

P450 isoform selectivity has been demonstrated in metabolite-P450 complex formation (Bensoussan et al., 1995; Sinal and Bend, 1995). The present study showed that DDB selectively inhibited CYP3A4-mediated testosterone 6β-hydroxylase activity in human liver microsomes. Our previous results demonstrated that DDB was metabolized to the catechol derivatives through the demethylation of methylenedioxybiphenyl moiety, and CYP3A4 was mainly involved in this reaction (Baek et al., 2001). These findings suggest that CYP3A4 generates a metabolic intermediate and is inactivated selectively by metabolite-P450 complex formation with DDB in human liver microsomes.

In conclusion, DDB formed a metabolite-P450 complex with P450 upon incubation with human liver microsomes in the presence of NADPH. In vitro studies using human liver microsomes demonstrated that the CYP3A4 activity was selectively inhibited during preincubation with NADPH in microsomes and that the formation of a quasi-irreversible metabolite-P450 complex with DDB was responsible for the time-dependent loss of CYP3A4 catalytic function. This inhibition may modulate the elimination of other coadministered drugs metabolized by CYP3A4.

Footnotes

  • This work was supported by National Research Laboratory Program from Korean Ministry of Science and Technology and grants from the Korean Ministry of Health and Welfare.

  • Abbreviations used are::
    DDB
    dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate
    PCN
    pregnenolone-16α-carbonitrile
    P450
    cytochrome P450
    • Received May 17, 2001.
    • Accepted August 22, 2001.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Babany G,
    2. Larrey D,
    3. Pessayre D
    (1988) Macrolide antibiotics as inducers and inhibitors of cytochrome P-450 in experimental animals and man. Prog Drug Metab 11:61–98.
  2. ↵
    1. Baek MS,
    2. Kim JY,
    3. Myung SW,
    4. Yim YH,
    5. Jeong JH,
    6. Kim DH
    (2001) Metabolism of DDB by human liver microsomal cytochrome P450: probable involvement of CYP3A and CYP1A2. Drug Metab Dispos 29:381–388.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Bensoussan C,
    2. Delaforge M,
    3. Mansuy D
    (1995) Particular ability of cytochrome P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol 49:591–602.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Chiba M,
    2. Nishime JA,
    3. Chen IW,
    4. Vastag KJ,
    5. Sahly YS,
    6. Kim BM,
    7. Dorsey BD,
    8. Vacca JP,
    9. Lin JH
    (1998) Metabolite-P450 complex formation by methylenedioxyphenyl HIV protease inhibitors in rat and human liver microsomes. Biochem Pharmacol 56:223–230.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Chiba M,
    2. Nishimi JA,
    3. Lin JH
    (1995) Potent and selective inactivation of human liver microsomal cytochrome P450 isoform by L-754-394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 275:1527–1534.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Dayer P,
    2. Leemann T,
    3. Striberni R
    (1989) Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin Pharmacol Ther 45:34–40.
    OpenUrlPubMed
  7. ↵
    1. Franklin MR
    (1991) Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 206:559–573.
    OpenUrlPubMed
  8. ↵
    1. Guengerich FP,
    2. Martin MV,
    3. Beaune PH,
    4. Kremers P,
    5. Wolff T,
    6. Waxman DJ
    (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051–5060.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Hodgson E,
    2. Philpot RM
    (1974) Interactions of methylenedioxy phenol (1,3-benzodioxole) compounds with enzymes and their effects on mammals. Drug Metab Rev 3:231–301.
    OpenUrlPubMed
  10. ↵
    1. Kim SN,
    2. Kim SY,
    3. Yim SY,
    4. Lee WY,
    5. Ham KS,
    6. Kim SK,
    7. Yoon MY,
    8. Kim YC
    (1999) Effect of dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylene dioxybiphenyl-2,2′-dicarboxylate (DDB) on chemical induced liver injury. Biol Pharm Bull 22:93–95.
    OpenUrlPubMed
  11. ↵
    1. Kim SG,
    2. Nam SY,
    3. Chung HC,
    4. Hong SY,
    5. Jung KH
    (1995) Enhanced effectiveness of dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylene dioxybiphenyl-2,2′-dicarboxylate in combination with garlic oil against experimental hepatic injury in rats and mice. J Pharm Pharmacol 47:678–682.
    OpenUrlPubMed
  12. ↵
    1. Lee HS,
    2. Kim YT,
    3. Jung HC,
    4. Yoon YB,
    5. Song IS,
    6. Kim CY
    (1991) Prospective randomized controlled trial with biphenyl dimethyl dicarboxylate in chronic active liver diseases: the effects on lowering serum alanine aminotransferase levels. Korean J Int Med 40:173–178.
    OpenUrl
  13. ↵
    1. Lee H,
    2. Yeom HY,
    3. Choi JS,
    4. Kim YG,
    5. Jin CB,
    6. Yoon CN,
    7. Kim DH
    (1998) Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem Pharmacol 55:1369–1375.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Lee HS,
    2. Jin CB,
    3. Park JS,
    4. Kim DH
    (1994) Modulation of cytochrome P-450 activities by 7,8-benzoflavone and metabolites. Biochem Mol Biol Int 34:483–491.
    OpenUrlPubMed
  15. ↵
    1. Leeman T,
    2. Transon C,
    3. Dayer P
    (1993) Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29–34.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Liu KT,
    2. Lesca P
    (1982) Pharmacological properties of dibenzo [a, c]cyclooctene derivatives isolated from Fructus schizandrae chinensis III. Inhibitory effects on carbon tetrachloride-induced lipid peroxidation, metabolism and covalent binding of carbon tetrachloride to lipids. Chem Biol Interact 41:39–47.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Mansuy D,
    2. Battioni J-P,
    3. Chottard J-C,
    4. Ullrich V
    (1979) Preparation of a porphyrin-iron-carbene model for the cytochrome P450 complexes obtained upon metabolic oxidation of the insecticide synergists of the 1,3-benzodioxole series. J Am Chem Soc 101:3971–3973.
    OpenUrlCrossRef
  18. ↵
    1. Marcus CB,
    2. Murray M,
    3. Wilkinson F
    (1985) Spectral and inhibitory interactions of methylenedioxyphenyl and related compounds with purified isozymes of cytochrome P-450. Xenobiotica 15:351–362.
    OpenUrlPubMed
  19. ↵
    1. Murray M,
    2. Hetnarski K,
    3. Wilkinson CF
    (1985) Selective inhibitory interactions of alkylmethylenedioxybenxenes towards monooxygenase activity in rat hepatic microsomes. Xenobiotica 15:369–379.
    OpenUrlPubMed
  20. ↵
    1. Murray M,
    2. Reidy GF
    (1990) Selectivity in the inhibition of mammalian cytochrome P450 by chemical agents. Pharmacol Rev 42:85–101.
    OpenUrlPubMed
  21. ↵
    1. Omura T,
    2. Sato R
    (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–2378.
    OpenUrlFREE Full Text
  22. ↵
    1. Peter R,
    2. Bocker R,
    3. Beaune PH,
    4. Iwasaki M,
    5. Guengerich FP,
    6. Yang CS
    (1990) Hydroxylation of chlorzoxazone as a specific probe for human lover cytochrome P450 2E1. Chem Res Toxicol 3:566–573.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Philpot RM,
    2. Hodgson E
    (1972) The production and modification of cytochrome P450 difference spectra by in vivo administration of methylenedioxyphenyl compounds. Chem Biol Interact 4:185–194.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Relling MV,
    2. Aoyama T,
    3. Gonzalez FJ,
    4. Meyer UA
    (1989) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450 in the CYP2C subfamily. J Pharmacol Exp Ther 252:442–447.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Sinal CJ,
    2. Bend JR
    (1995) Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat by nortriptyline. Mol Pharmacol 42:931–938.
    OpenUrlAbstract
  26. ↵
    1. Yu HQ,
    2. Yang XU,
    3. Zang YX,
    4. Shi JZ
    (1987) Biphenyl-dimethyl dicarboxylate in treating and preventing hepatitis due to drug poisoning. Chinese Med J (Peking) 100:122–123.
    OpenUrl
  27. ↵
    1. Yun C-H,
    2. Shimada T,
    3. Guengerich FP
    (1991) Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 40:679–685.
    OpenUrlAbstract
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 29 (12)
Drug Metabolism and Disposition
Vol. 29, Issue 12
1 Dec 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of the Selectivity and Mechanism of Cytochrome P450 Inhibition by Dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Characterization of the Selectivity and Mechanism of Cytochrome P450 Inhibition by Dimethyl-4,4′-dimethoxy-5,6,5′,6′-
dimethylenedioxybiphenyl-2,2′-dicarboxylate

Ji-Yeon Kim, Minsun Baek, Sooyong Lee, Sung-Ok Kim, Mi-Sook Dong, Bok-Ryang Kim and Dong-Hyun Kim
Drug Metabolism and Disposition December 1, 2001, 29 (12) 1555-1560;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Characterization of the Selectivity and Mechanism of Cytochrome P450 Inhibition by Dimethyl-4,4′-dimethoxy-5,6,5′,6′-
dimethylenedioxybiphenyl-2,2′-dicarboxylate

Ji-Yeon Kim, Minsun Baek, Sooyong Lee, Sung-Ok Kim, Mi-Sook Dong, Bok-Ryang Kim and Dong-Hyun Kim
Drug Metabolism and Disposition December 1, 2001, 29 (12) 1555-1560;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Olanzapine Glucuronidation in Humanized Mice
  • rs2242480 Regulates the Expression of CYP3A4 and CYP3A5
  • Absorption, Metabolism, and Excretion of Taselisib
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics